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Figure 1  Scatter plots of sarin inhalation exposure and percentage change in activity of a) red blood cell, b) 
plasma, c) whole blood, and d) unspecified cholinesterase. e) Sarin dermal exposure and percentage change 
in activity of unspecified cholinesterase.  
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Figure 2 Non-parametric kernel regression estimate and 95% CIs for sarin inhalation exposure and 
percentage change in red blood cell cholinesterase activity, with a) chemical protection (n = 326) and b) no 
protection (n = 332).  
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Figure 3 Non-parametric kernel regression estimate and 95% CIs for sarin dermal exposure and percentage 
change in unspecified cholinesterase activity, with a) physical protection (n = 185), and b) no protection (n 
= 88).  
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The effects of exposure to chemical warfare agents in humans are topical.  Porton Down is 
the UK’s centre for research on chemical warfare where, since WWI, a programme of 
experiments involving approximately 30,000 participants drawn from the UK armed services 
has been undertaken.   
Objectives 
Our aim is to report on exposures to nerve agents, particularly sarin, using detailed exposure 
data not explored in a previous analysis. 
Methods 
In this paper we have used existing data on exposures to servicemen who attended the human 
volunteer programme at Porton Down to examine exposures to nerve agents in general and to 
sarin in particular. 
Results 
Six principal nerve agents were tested on humans between 1945 and 1987.  Of all 4,299 nerve 
agent tests recorded, 3,511 (82%) were with sarin, most commonly in an exposure chamber, 
with inhalation being the commonest exposure route (85%).  Biological response to sarin 
exposure was expressed as percentage change in cholinesterase activity and, less commonly, 
change in pupil size. For red blood cell cholinesterase, median inhibition for inhalation tests 
was 41% (IQR 28-51%), with a maximum of 87%.  For dermal exposures the maximum 
inhibition recorded was 99%.  There was a clear association between increasing exposure to 
sarin and depression of cholinesterase activity but the strength and direction of the 
association varied by exposure route and the presence of chemical or physical protection. 
































































Pupil size decreased with increased exposure but this relationship was less clear when 
modifiers, such as atropine drops, were present. 
Conclusions 
These results, drawn from high quality experimental data, offer a unique insight into the 
effects of these chemical agents on humans. 
 
  

































































Nerve agents are organophosphate chemicals designed for use as chemical weapons. They act 
by the irreversible inhibition of acetyl cholinesterase in synapses and neuromuscular 
junctions, resulting in a build-up of toxic levels of acetylcholine. The effects of nerve agents, 
and other organophosphate compounds, can be counteracted by atropine and pralidoxime 
chloride. Atropine antagonises the muscarinic effects and some central nervous system 
effects of nerve agent exposure. Pralidoxime and other oximes act by reversing 
acetylcholinesterase phosphorylation. These effects are seen in organs with nicotinic 
receptors, such as skeletal muscle. Before exposure, pyridostigmine, which reversibly binds 
to acetyl cholinesterase, may be administered as a pre-treatment (Sidell and Borak 1992).   
Nerve agents were first developed by German chemists in the 1930s. Their discovery was the 
result of research into possible new pesticides (Coleman 2005). They were weaponised by 
German forces in WWII but were not used in combat during the war. Since then, nerve agents 
have been produced in considerable quantities by some countries, but rarely used; they were 
used in attacks against Iranian troops by Iraq (1980-88) and have been used against civilians, 
most notably against Kurdish civilians in Iraq at Halabja in 1988, on the Tokyo underground 
in 1995, and more recently in Syria (Organisation for the Prohibition of Chemical Weapons 
2017, 2017). Although the use and stockpiling of all chemical weapons is prohibited by the 
Chemical Weapons Convention, the possibility that they might be used is a recurrent concern 
(Organisation for the Prohibition of Chemical Weapons 1997).  
Porton Down is the UK’s centre for research on chemical warfare. Since WWI it has 
undertaken a programme of experiments using participants drawn from the UK armed 
services. Since 1916, approximately 30,000 service personnel have taken part.  Before WWII, 
Porton Down scientists had determined that organophosphates were a class of chemicals from 
































































which a chemical weapon might be derived but the focus of their research, iso-propyl 
fluorophosphate (PF-3), was not considered toxic enough to be a useful weapon (Ministry of 
Defence 2006). The first nerve agent tested at Porton Down was from a captured German 
shell in 1945 (Hinsley and Howard 1990) and after April 1945 Porton Down included nerve 
agents in the human testing programme. Over 4,000 tests with six nerve agents were recorded  
on over 3,000 participants between 1945 and 1987 (Keegan et al. 2009).  Most tests involved 
sarin (GB) and these took place during the 1950s (Keegan et al. 2009). Three other nerve 
agents (GA, GD and GE) were tested only in the 1940s and 1950s while two (GF and VX) 
were not extensively tested on humans and were not tested after the end of the 1960s.  
In our previous paper we reported on exposures to all chemicals in the ‘human volunteer 
programme’ (Keegan et al. 2009). In that study, we documented every test carried out as part 
of the programme at Porton Down 1941-1989, grouped documented chemicals into broad 
categories based on intended use (vesicant, nerve agent, lachrymator etc.), and assessed the 
number of people exposed to each chemical.  We included servicemen in our analyses of 
mortality and cancer incidence, excluding a small number of servicewomen and civilians 
(Carpenter et al. 2009; Venables et al. 2009).  In the current paper, we concentrate on 
exposures to nerve agents, and in particular sarin, for which we collected additional detailed 
exposure data not explored in the previous analysis. 
In this paper we report on all sarin exposures recorded in cohort members at Porton Down for 
the complete period of nerve agent testing, when the sarin tests took place and on the 
intensity and duration of exposure. Sarin exposures account for over 80% of nerve agent 
exposure to humans at Porton Down. Additionally, we describe the acute biological response 
to nerve agent exposure with and without the presence of exposure modifiers (e.g.  
pharmacological pre-treatments) or physical barriers (e.g. protective clothing).   However, the 
paper focuses on the experience of volunteers in nerve agent tests at Porton Down rather than 
































































on refining human nerve agent exposures, and an important feature of the paper is that little 
of the material reported here has previously appeared in the public domain. 
Methods 
Data abstraction 
Briefly, the UK Ministry of Defence made available a collection of archival material of 
contemporaneous records of experiments which were part of the programme at Porton Down 
between 1941 and 1989.   Details of the sources of exposure data are documented elsewhere 
(Keegan et al. 2007; Keegan et al. 2009).  
For all chemical tests, the research team recorded which chemical or chemical mixture was 
the focus of the test (ignoring other chemicals such as diluents or skin cleansers), exposure 
state (e.g. solid or liquid) and route of exposure (e.g. dermal, inhalation).  For nerve agents, 
more detailed exposure information was collected.  Details of data abstraction procedures 
have been published previously (Keegan et al. 2009). 
Exposure measures  
Exposure route was coded, by the researchers, as dermal only, ocular only, or not recorded. 
For any nerve agent test in which a person was exposed to a nerve agent gas/vapour in a 
chamber while wearing no protective equipment, the exposure route was coded as inhalation 
(± other routes), since it was assumed that in these circumstances the principal exposure route 
would be via the respiratory tract.   
Most nerve agent exposures took place in an exposure chamber, and chamber exposure was 
documented contemporaneously as the product of the concentration of sarin in the chamber 
air and the duration of exposure (Ct) expressed in mg.min/m
3
.  Although Ct is a cumulative 
exposure parameter we have termed it exposure ‘intensity’ because exposures were usually of 
































































short duration.  Where Ct was available from both the experiment record and the separate 
chamber record, the chamber value was used.  If necessary, exposure as Ct was calculated 
from concentration (as mg/m
3
) and duration (as minutes) from recorded data.  From 661 
inhalation tests for which a Ct was not documented, we were calculate 47 further Cts. 
Dermal exposures were applied in drops, usually to the skin of the inside forearm, and were 
mostly quantified as a known weight of nerve agent in mg. These dermal tests also took place 
in a chamber.  
Chemical classification 
The methods used to identify and categorise chemicals have been published (Keegan et al. 
2009). Briefly, individual chemical names documented in the Porton Down experiment books 
initially identified as possible nerve agents by the research team were confirmed (or not) by 
Porton Down scientists with relevant expertise. Chemical names which were synonyms or 
structural analogues were grouped together under a project agent name. For example: the 
nerve agent soman (CAS registry number: 96-64-0)  documented as ‘soman’, was assigned as 
the project agent name.  Synonyms, such as GD, pinacolylmethylphosphonyl fluoride or 
1,2,2trimethylpropofluoro(methyl)phosphine oxide, were coded as soman, as were functional 
analogues, such as tridecylmethylphospono fluoridate. In this paper nerve agents are reported 
using their project agent name (see table 1).  
Protection status 
For antidotes or pre-treatments, only the presence or absence of the chemical was recorded. 
Data relating to whether a test exposure was modified by physical protection were combined 
in this study as: yes to respirator use, non-protective or protective clothing or equipment. For 
respirator use, the categories ‘no’ and ‘not known’ were combined.  No information was 
available on the type of respirator used.  
































































Data relating to whether a test exposure was modified by chemical protection were combined.  
Typical chemicals documented as having been used in tests with sarin were atropine and 
pralidoxime.  
Cholinesterase 
Porton Down assayed three types of cholinesterase over time: unspecified, whole blood, red 
blood cell and plasma. We have taken red blood cell cholinesterase as the primary measure, 
where available.   As units of cholinesterase measurement were not consistently applied over 
the study period, the percentage change in cholinesterase activity was used as the measure of 
acute biological effect.  Whenever possible this was calculated from the pre- and post-
exposure values.  Percentage change was abstracted when this was the only measure 
recorded. Where more than one post-exposure value was documented, the lowest was used.  
The percentage change in pupil diameter was used to assess the acute effect of nerve agent 
exposure. Documented measures (in mm) were for both right and left eye, for right or left eye 
alone, or for a single (unspecified) eye. The primary measure used here was change in right 
eye pupil size.  If not available, change in left eye pupil size was used and, if that was not 
available, single (unspecified) eye. Correlation between left and right eye measurements was 
good (Pearson’s coefficient 0.89). Our data indicate that the resolution of pupil diameter 
measurement was approximately 0.25mm. 
Statistical analysis 
Statistical analysis of data was performed  using STATA v11.0 (StataCorp 2009).  As 
distributions of many of the exposure parameters were positively skewed, these were 
primarily described using a median and interquartile range (IQR).  Maximum exposure 
intensities and durations are also reported. Non-parametric kernel regression was used to 
model the association between exposure as the predictor variable and acute biological 
































































response (the outcome variable).  The kernel regression was carried out using the lpoly 
command in STATA, on untransformed data using the default Epanechnikov kernel function 
and 0 degrees of smoothing). These regressions give a non-parametric smoothed regression 
estimate which does not make any assumptions about the functional form of the relationship 
(Royston et al. 1999).  
Ethical approval 
Ethical approval for the epidemiological studies of Porton Down veterans was granted by the 
South East Multicentre Research Ethics Committee, the Defence Medical Services Clinical 
Research Committee, and the Patient Information Advisory Group. The Ministry of Defence 
provided access to data and was represented on the Medical Research Council’s project 
monitoring group but had no role in the abstraction of data, analysis, or interpretation of the 
results.  
Results 
Chemicals tested and dates of tests 
Human tests with nerve agents at Porton Down took place between April 1945 and December 
1987 (Table 1). During that period six nerve agents were tested in a total of 4,299 tests, on 
3,597 individuals. Most (75%) tests with nerve agents were completed by 1959. The most 
commonly-tested nerve agent was sarin, which accounted for 3,511 (82%) of the 4,299 nerve 
agent tests. The second most-tested nerve agent was tabun (GA), tested 398 times (9% of 
tests) on 262 individuals. Other nerve agents tested were soman (GD), cyclo-sarin (GF) and 
VX.  
































































Sarin exposure route and protection use 
Of all nerve agent tests carried out at Porton Down (n = 4,299), 80% (n = 3,511) were with 
Sarin.  Most sarin tests (2,860 of 3,511, 82%) took place in an experimental chamber. 
Inhalation was the most common exposure route (2,972, 85% of all sarin tests, Table 2). Only 
288 (8%) of tests were dermal. A small number of sarin tests were directly to the eye (110, 
3%).  
Forty-seven percent of sarin tests took place with some kind of physical or chemical 
protection (Table 2).  In 665 (19%) sarin tests the participant was wearing a respirator, and 
this figure was slightly lower in tests by the inhalation route (470, 16%). Information on the 
type of respirator used was not available in this dataset. Physical protection (such as a patch 
of fabric under test) was present in 897 (25%) of sarin tests, and chemical protection (such as 
treatment with pralidoxime) in 577 (16%)..  In 53% of sarin tests no modifier was present. 
Exposure intensity 
Median sarin inhalation exposure intensity was 12.8 mg.min/m
3
 (Table 3). Most (2,229, 75%) 
of the participants in sarin tests had exposures to sarin of <15 mg.min/m
3
. The maximum 
inhalation exposure to sarin was recorded as 48.5 mg.min/m
3
 (in 1967), but all tests with 
sarin at exposure intensities over 15 mg.min/m
3
 were in the presence of (physical) protection, 
except 22 single breath inhalation tests (range 15 to 19.6 mg.min/m
3
).  Median Ct varied by 
protection status. It was lowest in tests with physical protection present and highest in tests 
with chemical protection only.  
Median dermal exposure intensity for sarin exposures was 200 mg (IQR 8-250 mg). The 
maximum dermal sarin exposure was 300 mg (Table 3). Most (188, 65%) dermal exposures 
had physical protection present, often a small piece of fabric taped to the skin onto which the 
drop of sarin was administered. All dermal sarin exposures took place before February 1953.  
































































Duration of exposure 
The median duration of all sarin exposures, and of inhalation exposures, was 15 minutes.  
The duration was shorter in inhalation tests where physical protection was present (2 mins).  
The duration of sarin dermal exposures was 30 mins in all but one test (Table 4). There were 
153 unprotected sarin inhalation tests whose duration was greater than 60 minutes but in none 
of these did the exposure intensity exceed 16.2 mg.min/m
3
.  There were two tests with 
recorded durations of 400 minutes and these were with low chamber concentrations of 0.005 
mg/m
3
, resulting in an exposure of 2 mg.min/m
3
.  
Measures of acute biological effect 
Table 5 shows the numbers of sarin inhalation and dermal tests for which data were available 
on both exposure and acute biological response.  Unspecified cholinesterase was a measure 
used only in the 1950s, in 692 tests.  All dermal tests where a biological effect was assessed 
had cholinesterase inhibition measured using unspecified cholinesterase.  In most tests after 
the end of the 1950s three cholinesterase types were measured:  red blood cell, plasma and 
whole blood, though more whole blood measures overall were made as it was the sole 
measure of biological effect in some tests in the 1950s. 
Table 6 shows the median and maximum cholinesterase inhibition by cholinesterase type and 
exposure route.  For dermal exposures, only unspecified cholinesterase was available.  For 
inhalation exposures the median cholinesterase depression was greatest for red blood cell 
cholinesterase. There are marked differences in the cholinesterase inhibition by 
cholinesterase type for ocular exposures. 
For sarin inhalation exposures overall there was a median red blood cell cholinesterase 
inhibition of 41% (IQR 24-51). When stratified by protection type little difference was noted 
in this median inhibition, though it was least (33%) in tests where no protection was present 
































































(Table 7).  In dermal tests with physical protection the median cholinesterase depression was 
31%.  
Relationship between sarin exposure intensity and cholinesterase activity 
There were 2,353 sarin inhalation tests with a measure of exposure intensity (Ct) and in 1,436 
(61%) of these a cholinesterase measure had also been documented.  For dermal tests the 
figures were 282 and 273 (96%) respectively (Table 5).  In sarin inhalation tests, red blood 
cell cholinesterase activity decreased with increasing unprotected exposures (Figure 1).  Non-
parametric kernel regression of the untransformed data indicates a exposure-response 
relationship between unprotected inhalation exposure to sarin and red blood cell 
cholinesterase inhibition (Figure 2).  For dermal sarin tests (Figure 3) with physical 
protection there was a exposure-response relationship between exposure and cholinesterase 
inhibition. Figure 3 also shows that in dermal exposures >200 mg with physical protection 
there was pronounced variation in inhibition of cholinesterase activity.  In 11 of these tests 
the maximum inhibition was >80% in and >90% in 5 tests.  When there was no protection 
present, maximum dermal exposure did not exceed 44 mg and the maximum decrease in 
cholinesterase activity was 50%.  
Pupil size 
Between May 1949 and December 1980 pupil size was one of the measures used to assess the 
effect of nerve agent exposure, 90% of these tests taking place before 1973. Pupil diameter 
decreased with increasing exposure, and with decreased red blood cell cholinesterase activity 
in unprotected inhalation tests (Table 8).  The direction and magnitude of the relationships 
was less clear, or even reversed, when protection was present. 

































































In our earlier papers, we documented the numbers of participants exposed to nerve agents, 
and examined the cause specific mortality and cancer incidence in those exposed (Carpenter 
et al. 2009; Keegan et al. 2009; Venables et al. 2009).  This paper now presents in greater 
detail information on tests with nerve agents, including exposure-response relationships for 
acute effects. 
 Most nerve agent tests were with sarin, and for most of those tests the exposure route was via 
inhalation, with dermal tests also taking place between October 1951 and May 1953.  The 
resultant change in cholinesterase activity was high in some tests (a depression of around 
90%).  Indeed, in May 1953, a national serviceman, Ronald Maddison, died as a result  of his 
exposure to sarin (Ministry of Defence 2006).  He had taken part in a dermal test with an 
exposure of 200 mg of sarin.  A subsequent report into the tragedy, and more widely into 
testing involving servicemen, was compiled by a committee led by the then president of the 
Royal Society, Lord Adrian.  It concluded that nerve agent exposures should not exceed a Ct 
of 15 mg.min/m
3
 and should be to sarin only (Ministry of Defence 2006).  The inquest into 
Ronald Maddison’s death, held in camera, returned a verdict of accidental death. However, 
the inquest was reopened and in 2004 returned a verdict of unlawful killing (Schmidt 2006). 
These data give a rare insight into cholinesterase activity after nerve agent exposure and 
indicate that in unprotected tests there was a clear relationship between increasing exposure 
and decrease in red blood cell cholinesterase, and one of the strengths of our study is that not 
only was red blood cell cholinesterase reported consistently across three decades but it is also 
a good predictor of synaptic cholinesterase activity (Bajgar 1992; Bajgar 2004).  The use of 
just one of the three measure of cholinesterase activity in our analysis of the exposure-
response relationship was intended to minimise uncertainly in validity of exposure measures 
































































which would have arisen with use of different biomarkers of cholinesterase activity. Of the 
three cholinesterase measures available to us, whole blood cholinesterase activity is 
considered an acceptable marker for organophosphate exposure but further inference from it 
is limited (Bajgar 2004). Both red blood cell cholinesterase and plasma cholinesterase are 
informative but plasma cholinesterase is understood to capture change in the activity of 
butrylcholinesterase, whose physiological function is unknown (Marrs et al. 2007).  
Variability of cholinesterase response to sarin exposures, both inhaled and dermal, was high.  
For example, in sarin exposures of 15 mg.min/m
3
, the cholinesterase inhibition varied 
between 5% to 60%. The variability when either chemical or physical protection was present, 
for both inhalation and dermal exposure routes, was greater at higher exposure intensities.  
This may not reflect inability of protective measures to prevent exposure, but the wide range 
of types of protection, particularly physical. Details of the exact chemical modifier present 
during each test were not captured in this dataset but could be examined in a future analysis.  
Part of the variability in response might be biological. Whilst the range of natural annual 
within-individual variation in red blood cell cholinesterase is 8% of the annual mean (Sidell 
and Kaminskis 1975), annual within-individual variability in plasma cholinesterase is higher 
and may be 25%. It has been suggested that, in an individual, a change in red blood cell 
cholinesterase of more than 8% should ‘alert one to look for a cause’ (Sidell and Kaminskis 
1975).  Our data did not allow for an assessment of within-individual variation because our 
analysis is at the level of the test and repeated exposures to individuals were uncommon.   
In a study of workers exposed to organophosphate pesticides, full body protection (not 
including respiratory protection) significantly attenuated the effect of the pesticides on 
cholinesterase activity whereas face and glove protection alone did not (Lander and Hinke 
1992). The effect of physical protection was not clear in our data, which may be related to the 
































































heterogeneity of the physical materials placed between the exposure and the skin.  No clear 
effect of chemical protection was seen in our data; again, there was heterogeneity in types of 
chemical protection employed.    
One known ocular effect of organophosphates is constriction of the pupil, or miosis (Nozaki 
et al. 1997).  Our results show that in unprotected tests the pupil constricted as exposure 
intensity increased.  Sarin also causes eye pain and visual disturbances (Sidell and Borak 
1992) which add to its impact on military effectiveness (Ministry of Defence 2006).  
Research at Porton Down in the 1940s and early 1950s had shown that the single exposure 
threshold at which miosis, but no other symptom, was apparent was 3.3 mg.min/m
3
, leading 
to a recommendation that miosis be considered a marker for exposure to a low concentration 
of nerve agent (Ministry of Defence 2006).  Other early studies at Porton Down on the effects 
of tabun on visual acuity showed a linear relationship between tabun exposure and decrease 
in pupil diameter ((Marrs et al. 2007). Miosis is still a clinically-relevant marker of exposure: 
in a study of people exposed to sarin in the terrorist attack on the Tokyo underground in 
1995, it was found that red blood cell cholinesterase activity was significantly lower in 
people who were miotic (pupil size <3mm) than those who were not (Nozaki et al. 1997). 
The response measure percentage change in pupil diameter was calculated from before- and 
after-exposure measurements of pupil diameter in millimetres. The most commonly-noted 
changes were 0 mm (15%), 1 mm (15%), 1.25 mm (18%) and 1.5 mm (16%). Pupil size was 
used as a response measure over a ten-year period (1949-1959).  
In our data the effect on the eye of unmodified exposure to sarin was to decrease pupil 
diameter. This decrease in pupil diameter was not apparent when the exposure to sarin was 
modified by chemical protection; the effect then was to increase the diameter of the pupil. 
This may be because in-test protection against nerve agents was provided by pre-treatment 
































































with pyridostigmine which, like sarin, is an acetylcholine antagonist (but which unlike sarin 
has an effect that is reversible).  The effect of exposure with physical protection was 
statistically significantly smaller than that observed with no protection. Physical protection 
comprises a variety of protective measures, including respirator use, and this result would 
indicate that measures were successful in limiting exposure. However, some materials coded 
as protective, such as textiles used for military uniforms, were under test for their protective 
efficacy but  later were found to increase dermal exposure by limiting evaporation of nerve 
agents (Ministry of Defence 2006; Organisation for the Prohibition of Chemical Weapons 
2015). The increase in cholinesterase depression with dermal exposure could be explained by 
this effect. The lack of cholinesterase depression shown in unprotected dermal exposures is 
likely the result of the smaller quantities administered (maximum 40 mg) compared to those 
given with protection (maximum 300 mg).  
Chamber exposures were expressed as ‘Ct’, the product of concentration (C) and time (t).  
While Haber’s law would imply that the identical products of C x t will provoke identical 
biological responses, this is often true only for a set range of concentrations (Witschi 1999).  
A high concentration of nerve agent administered in a short time could be lethal and a low 
concentration for a longer time effectively harmless.  For example, an exposure of 300 mg/m
3 
for 3 seconds and exposure of 0.15 mg/m
3 
for 100 minutes both result in a Ct of 15 
mg.min/m
3
, but the former would result in a chamber concentration of 48 ppm sarin, the latter 
0.025 ppm.  One estimate for the human LD50 of sarin is 1.2ppm (Ellison 2000).  In tests 
where the duration was 30 minutes, the chamber air concentrations during the tests would 
have been on average, 0.5 mg/m
3
 (0.08 ppm).  It has also been assumed that identical 
cumulative exposures, calculated as the product of different combinations of time and 
exposure concentration, are associated with identical risk of disease, but this too is an 
assumption that needs refining (Smith and Kriebel 2013).  
































































Since nerve agents are banned under the Chemical Weapons Convention (Organisation for 
the Prohibition of Chemical Weapons 1997) and any human testing is likely to have been 
done by governments, and secretly, there is little in the open scientific literature with which 
to compare our findings. However, the US National Research Council has reported on the 
mortality of US veterans of a chemical testing programme at Edgewood Arsenal, finding no 
increase in all-cause or cause-specific mortality in 846 veterans of tests with anti-
cholinesterases (National Research Council and Committee on Toxicology 1985). Their 
exposure data are difficult to compare to ours because only a sample of all exposures was 
reported, and no acute biological response data were reported.    
Detailed internal technical reports on experiments with nerve agents were prepared at Porton 
Down and many are declassified and available from the UK National Archive.  Our data, 
containing as it does results of many experiments spanning decades, is unusual in its scale.  
However, it is acknowledged that the individual experiments were not designed to a standard 
template and there are therefore limitations to the inferences we can draw in an analysis of 
them as a single body.  Notwithstanding that, these results offer a unique insight into the 
experiments carried out with nerve agents at Porton Down in the five decades following 
WWII.  While chemical weapons have not been widely used in major conflicts during that 
period, their use, especially against civilians, has increased as formerly stable states 
possessing chemical arsenals have become destabilised.  
































































Table 1 Number of participants exposed to nerve agents at Porton Down 1945-1987. 
Chemicals 
(abbreviated name) 















 2,980 3,511 82 1 1949-87 1959 
Tabun (GA)
b
  262 398 9 2 1945-52 1951 
Soman (GD)
c
  141 149 4 1 1950-63 1952 
GE
d
 25 25 1 1 1949-50 1950 
Cyclo-sarin (GF)
e
 166 167 4 1 1950-64 1963 
VX
f
 48 49 1 1 1960-69 1969 
All nerve agents 3,622* 4,299 100 1 1945-87 1959 
 
a 
Iso-propylmethylphosphonofluoridate (CAS  
b 
Ethyl N,N- dimethylphosphoramidocyanidate 
c 
Pinacolyl methylphosphonofluoridate 
d Isopropyl ethylphosphonofluoridate   
e 
Cyclohexylmethyl phosphonofluoridate  
f O-ethyl S-diisopropylaminoethyl methyl phosphonofluoridate  
* Number of veterans exposed to any nerve agent = 3,597. N=25 veterans were exposed to more 
than one nerve agent. 
  
































































Table 2 Sarin tests by exposure route and presence of physical or chemical modifiers. 
 











Chemical only 567 (19) 0 2 (2) 8 (6) 577 (16) 
Physical only 669 (22) 194 (67) 26 (24) 8 (6) 897 (25) 
Respirator 468 194 0 1 663 
No respirator 201 0 26 7 234 
Chemical and physical 144 (5) 0 0 15 (11) 159 (5) 
Respirator 2 0 0 0 2 
No respirator 142 0 0 15 0  
None 1,592 (54) 94 (33) 82 (74) 110 (78) 1,878 (53) 
Total 2,972 (100) 288 (100) 110 (100) 141 (100) 3,511 (100) 
a
 +/- other exposure routes 
 
  
































































Table 3 Exposure intensity of sarin tests by exposure route and protection status. 
Exposure route and 
modifier type 






Chemical only 545 14.9 12.0-15.0  16.6 
Physical only 437 10.7 7.4-13.9 48.5 
Chemical and physical 144 12.3 10.3-12.9 44.9 
None 1,227 11.8 5.1-14.8 19.6 
Total 2,972 12.8 7.5-15.0 48.5 
Dermal only: (mg) 
Physical only 188 250.0 200-300.0 300.0 
None 94 0.50 0.3-8.0 44.0 
Total 288 200.0 8.0-250.0 300.0 
a
 +/- other exposure routes 
  

































































Table 4 Duration of sarin tests (mins) by exposure route and protection status. 




IQR (mins) Maximum 
(mins) 
Inhalationa:         
Chemical only 552 15.0 15.0-15.0 75.0 
Physical only 433 2.0 2.0-30.0 150.0 
Chemical and physical 144 2.0 1.7-2.0 30.0 
None 1,374 15.0 2.0-30.0 400.0 
Total (inhalation) 2,503 15.0 0.3-28.0 400.0 
Dermal only:         
Physical only 84 30.0 30.0-30.0 30.0 
None 1 5.0 n/a 5.0 
Total (dermal) 85 30.0 30.0-30.0 30.0 
a
 +/- other exposure routes 
 
































































Table 5 Number of sarin tests with exposure intensity and/or biological response data available, by decade. 
 Intensity inhalation
a













blood cell Plasma Unspecified 
1940s 108 0     0 0 0 0 173   
1950s 1,703 1,096 282 273 945 579 420 692 2,154 288 
1960s 214 195     266 271 270 0 286   
1970s 236 96     96 96 95 0 249   
1980s 92 49     51 46 46 0 110   
All 
years 
2,353 1,436 282 273 1358 992 831 692 2,972 288 
a




tests which contain a value for exposure intensity (Ct) and at least one measure of percentage change in cholinesterase (ChE) activity 

































































Table 6 Percentage inhibition in cholinesterase activity, by exposure route and type of 
cholinesterase. 








Inhalationa:        
Red blood cell 915 41 24-51 87 
Plasma 803 24 15-33 67 
Whole blood 1,327 32 18-42 93 
Unspecified 370 20 9-30 74 
Dermal only:     
Red blood cell 0 . . . 
Plasma 0 . . . 
Whole blood 0 . . . 
Unspecified 279 22 10-37 99 
Ocular only:        
Red blood cell 26 -1 -4-3 10 
Plasma 1 63 n/a 63 
Whole blood 4 40 19-52 58 
Unspecified 19 -1 -3-4 30 
Not recorded:        
Red blood cell 51 19 10-53 67 
Plasma 27 25 2-38 49 
Whole blood 27 40 3-51 60 
Unspecified 24 10 7-15 22 
Total:        
Red blood cell 992 40 21-51 87 
Plasma 831 24 15-33 67 
Whole blood 1,358 32 18-43 93 
Unspecified 692 19 9-32 99 
a
 +/- other exposure routes 
b
 Negative values indicate an increase in cholinesterase activity. 
  
































































Table 7 Percentage inhibition in red blood cell and unspecified cholinesterase, by 
exposure route and modifier type. 
Exposure route and 
protection status n Median (%) IQR (%) Maximum (%) 
Inhalation
a
: Red blood cell cholinesterase 
Chemical only 344 48 39-54 73 
Physical only 20 46 21-53 60 
Chemical and physical 2 47 40-54 54 
None 549 33 19-48 87 
Total 915 41 24-51 87 
Dermal only: Unspecified cholinesterase 
Physical only 191 31 19-46 99 
None 88 5 0-13 50 
Total 279 22 10-37 99 
a
 +/- other exposure routes 
  


































































Table 8 Results of linear regression of percentage change in pupil diameter on a) 
inhalation exposure (mg.min/m
3
), and b) percentage change in red blood cell 
cholinesterase activity, by protection status.  
Protection status n Βa const r2 p 
a) Pupil diameter v. Ct (mg.min/m
3
) 
Chemical only 196 -0.62 61.0 0.02 0.02 
Physical only 50 0.58 29.8 0.17 0.001 
Chemical and physical 138 0.22 43.2 <0.01 0.166 
None 360 2.60 26.0 0.43 <0.001 
b) Pupil diameter v. RBC cholinesterase 
Chemical only 55 -0.02 54.2 -0.02 0.87 
None 45 0.40 34.7 0.40 <0.001 
a
A negative coefficient indicates an increase in pupil diameter as sarin exposure increased. 

































































Figure 1  Scatter plots of sarin inhalation exposure and percentage change in activity of 
a) red blood cell, b) plasma, c) whole blood, and d) unspecified cholinesterase. e) Sarin 











































































































































































































































Unspecified cholinesterase and sarin dermal exposure
(b) (a) 
R2 = 0.62 
(c) 
R2 = 0.51 
(d) 
R2 = 0.71 
(e) 
R2 = 0.60 
R2 = 0.6 
































































Figure 2 Non-parametric kernel regression estimate and 95% CIs for sarin inhalation 
exposure and percentage change in red blood cell cholinesterase activity, with a) 




















































kernel = epanechnikov, degree = 0, bandwidth = .68, pwidth = 1.02














































kernel = epan2, degree = 0, bandwidth = 1.39, pwidth = 2.09
Red blood cell cholinesterase with no protection(a) (b) 

































































Figure 3 Non-parametric kernel regression estimate and 95% CIs for sarin dermal exposure and percentage change in unspecified 
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